Chemomab Therapeutics Ltd. (CMMB) Stock News, Apr-Nov 2025

Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Dr. Adi Mor will deliver a prerecorded corporate presentation, which will be available from September 5, 2025, at 7:00 am ET for 90 days via webcast. The company's management team will also conduct one-on-one investor meetings on September 8-9, 2025.

Chemomab Therapeutics (Nasdaq: CMMB) reported Q2 2025 financial results and provided updates on its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources. Key financial metrics include cash position of $9.5 million as of June 30, 2025, with runway through Q2 2026.

Notable developments include FDA alignment on CMC standards and toxicology testing requirements, new patent issuances in China and Russia, and multiple presentations of Phase 2 SPRING trial data at major scientific meetings. The company also announced plans to implement an ADS ratio change from 1:20 to 1:80 effective August 26, 2025, essentially functioning as a 1:4 reverse split for ADS holders.

Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.

The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.

The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.

Chemomab Therapeutics (NASDAQ: CMMB) has received positive feedback from two FDA meetings regarding the advancement of nebokitug to Phase 3 trials for Primary Sclerosing Cholangitis (PSC). The FDA agreed with Chemomab's Chemistry, Manufacturing, and Controls (CMC) strategy for late-stage development and commercialization. Additionally, in a Type C meeting, the FDA permitted non-clinical fetal and embryo developmental toxicology studies to be conducted parallel to Phase 3 trials, with results to be submitted as part of the Biologics Licensing Application (BLA). These regulatory milestones follow previous positive discussions about the Phase 3 pivotal trial design in December, as the company continues discussions with potential strategic partners.

Chemomab Therapeutics (NASDAQ: CMMB) has secured new patent protections in China and Russia for its lead product nebokitug (formerly CM-101), extending coverage up to 2041. The Chinese patent (No. ZL 2018 8 0018207.8) covers nebokitug's use in hepatic diseases, including primary sclerosing cholangitis (PSC), through 2038. The Russian patent (RU Patent 2022125176) protects various formulations and doses through 2041. These additions strengthen Chemomab's intellectual property portfolio for nebokitug, which has shown promising Phase 2 SPRING trial results in PSC treatment. The company has received FDA alignment on a regulatory approval pathway for PSC, a debilitating disease currently lacking effective treatments. Chemomab is pursuing potential partnerships to support a Phase 3 registrational trial in PSC.

Chemomab Therapeutics (NASDAQ: CMMB) reported significant progress in Q1 2025 with its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company announced positive 48-week data from the SPRING trial, showing continued improvements in liver injury, inflammation, and fibrosis biomarkers. Notably, Chemomab aligned with FDA on a pathway to potential regulatory approval through a single, clinical-events-driven Phase 3 trial, positioning nebokitug to potentially become the first FDA-approved PSC treatment. Financial highlights include cash position of $10.6 million as of March 31, 2025, with runway extended to Q2 2026. R&D expenses decreased to $2.5 million from $3.1 million YoY, while net loss improved to $3.3 million from $3.9 million. The company is actively pursuing strategic partnerships to advance the Phase 3 program.

Chemomab Therapeutics (NASDAQ: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in treating Primary Sclerosing Cholangitis (PSC) at DDW 2025. The trial demonstrated that nebokitug was well-tolerated for up to 48 weeks of treatment and showed significant improvements in multiple fibrotic and inflammatory biomarkers. In the double-blind, placebo-controlled 15-week treatment period, the drug exhibited dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects. Notably, patients with moderate to advanced disease receiving the 20 mg/kg dose showed sustained improvement in fibrosis markers, reduction in ELF scores, and stabilization of liver stiffness. These positive results support advancing nebokitug to Phase 3 clinical trials as a potential first-in-class treatment for PSC, a devastating progressive disease with no FDA-approved therapies.

Chemomab Therapeutics (Nasdaq: CMMB) has presented new positive clinical data at EASL 2025 supporting nebokitug's potential as a first-in-class treatment for Primary Sclerosing Cholangitis (PSC) and related fibro-inflammatory diseases.

The Phase 2 SPRING trial analysis revealed that nebokitug treatment resulted in dose-dependent improvements in multiple inflammatory and fibrotic biomarkers. A comprehensive proteomic analysis of 3,000 circulating proteins showed significant changes in proteins related to fibrosis, immune cell recruitment, and inflammation. The treatment led to downregulation of biological processes including cell-cell adhesion, extracellular matrix organization, and pathways involved in leukocyte migration.

Pharmacokinetic analyses demonstrated dose-proportional increases in nebokitug concentration, with steady-state levels achieved after the fourth dose. Linear regression analyses indicated trends between increasing patient exposure to nebokitug and decreasing levels of PSC disease biomarkers, including liver enzyme and transient elastography scores.

Chemomab Therapeutics (Nasdaq: CMMB) has announced upcoming presentations of clinical data for nebokitug (CM-101) in treating primary sclerosing cholangitis (PSC) at three major scientific conferences.

The presentations will take place at:

• DDW25 (May 3-6, 2025, San Diego) featuring an oral presentation by Dr. Paul Pockros on safety, tolerability, and biomarker improvements
• EASL 2025 (May 7-10, 2025, Amsterdam) with two poster presentations by CEO Adi Mor on pharmacokinetics, pharmacodynamics, and proteomic profile changes
• BSG LIVE'25 (June 23-26, 2025, Glasgow) featuring an oral presentation by Prof. Douglas Thorburn on the SPRING Study results

The presentations will focus on CM-101's impact on inflammation, fibrosis, and cholestasis in PSC patients.